Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14182-7. doi: 10.1073/pnas.1001296107. Epub 2010 Jul 21.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide. The oxygen-sensitive hypoxia inducible factor (HIF) transcriptional regulators HIF-1alpha and HIF-2alpha are overexpressed in many human NSCLCs, and constitutive HIF-2alpha activity can promote murine lung tumor progression, suggesting that HIF proteins may be effective NSCLC therapeutic targets. To investigate the consequences of inhibiting HIF activity in lung cancers, we deleted Hif-1alpha or Hif-2alpha in an established Kras(G12D)-driven murine NSCLC model. Deletion of Hif-1alpha had no obvious effect on tumor growth, whereas Hif-2alpha deletion resulted in an unexpected increase in tumor burden that correlated with reduced expression of the candidate tumor suppressor gene Scgb3a1 (HIN-1). Here, we identify Scgb3a1 as a direct HIF-2alpha target gene and demonstrate that HIF-2alpha regulates Scgb3a1 expression and tumor formation in human Kras(G12D)-driven NSCLC cells. AKT pathway activity, reported to be repressed by Scgb3a1, was enhanced in HIF-2alpha-deficient human NSCLC cells and xenografts. Finally, a direct correlation between HIF-2alpha and SCGB3a1 expression was observed in approximately 70% of human NSCLC samples analyzed. These data suggest that, whereas HIF-2alpha overexpression can contribute to NSCLC progression, therapeutic inhibition of HIF-2alpha below a critical threshold may paradoxically promote tumor growth by reducing expression of tumor suppressor genes, including Scgb3a1.
非小细胞肺癌(NSCLC)是全球癌症死亡的主要原因。在许多人类 NSCLC 中,氧敏感的缺氧诱导因子(HIF)转录调节剂 HIF-1α 和 HIF-2α 过表达,并且组成型 HIF-2α 活性可以促进小鼠肺肿瘤的进展,这表明 HIF 蛋白可能是有效的 NSCLC 治疗靶标。为了研究抑制肺癌中 HIF 活性的后果,我们在已建立的 Kras(G12D)驱动的小鼠 NSCLC 模型中删除了 Hif-1α 或 Hif-2α。Hif-1α 的缺失对肿瘤生长没有明显影响,而 Hif-2α 的缺失导致肿瘤负担意外增加,这与候选肿瘤抑制基因 Scgb3a1(HIN-1)的表达降低有关。在这里,我们将 Scgb3a1 鉴定为 HIF-2α 的直接靶基因,并证明 HIF-2α 调节人类 Kras(G12D)驱动的 NSCLC 细胞中的 Scgb3a1 表达和肿瘤形成。据报道,AKT 途径活性被 Scgb3a1 抑制,在 HIF-2α 缺陷型人类 NSCLC 细胞和异种移植物中增强。最后,在大约 70%分析的人类 NSCLC 样本中观察到 HIF-2α 和 SCGB3a1 表达之间的直接相关性。这些数据表明,尽管 HIF-2α 的过表达可能有助于 NSCLC 的进展,但 HIF-2α 的治疗性抑制低于临界阈值可能通过降低肿瘤抑制基因(包括 Scgb3a1)的表达而反相促进肿瘤生长。